Latest News

Evotec and BMS intensify R&D on protein degraders

© Evotec SR


Hamburg-headquartered Evotec SE has extended and expanded its three-year-old partnership with Bristol Myers Squibb in targeted protein degradation ("molecular glue degraders") for an additional eight years. 

The small molecule degraders link an E3 ubiquitin ligase with the molecular target, mostly in cancer and autoimmunity indications. The interaction results in ubiquitination and subsequent degradation of the recruited protein and is hoped to provide a ong-lasting therapeutic effect.

Bristol Myers Squibb brings in a huge library of E3 ligase modulators. Under the terms of the agreement, both parties will leverage all of Evotec’s appropriate platforms as well as AI/ML-based drug discovery.

Under the new agreement, Evotec cashes in an upfront payment of $200m and is eglible to obtain up to $5bn in milestone payments and tiered royalties on product sales. 

German HTGF IV fund closes at €493m

Alongside the Federal Ministry of Economics and Climate Protection (BMWK) and KfW Capital, 45 private investors (companies) participated in HTGF IV...

Mainz Biomed Partners with Microba Life Sciences

Leveraging a platform for measuring the human gut microbiome to discover and develop novel therapeutics for major diseases, Microba and Mainz Biomed...

The innovative power of the chemical industry assembled

From cosmetics to medical treatments, from agriculture to the fabrics that make out our clothes – chemistry is ubiquitously needed in countless...

uniQure sells royalty interest in gene therapy for $400m

Tay Therapeutics in licensing deal with VYNE Therapeutics

Tay Therapeutics Ltd’s exclusive license deal with VYNE Therapeutics Inc. on the oral BET inhibitor, TAY-B2 (now known as VYN201) forsees an upfront...

Dutch State to sell share capital of Intravacc BV

Two years after the establishment of the private company Intravacc BV (Bilthoven, The Netherlands), the sale of the former Netherlands Vaccine...

Genmab and argenx combine antibody know-how

Genmab A/S and argenx will start their collaboration jointly launching two antibody programmes in immunology and oncology with the...